- Conditions
- Non-obstructive Hypertrophic Cardiomyopathy
- Interventions
- mavacamten, Placebo
- Drug
- Lead sponsor
- MyoKardia, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 32
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 28 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–22
of 22
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hypertrophic Cardiomyopathy
- Interventions
- mavacamten
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • New Haven, Connecticut • Durham, North Carolina + 1 more
- Conditions
- Cardiomyopathy, Hypertrophic
- Interventions
- Mavacamten, Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 26 more
- Conditions
- Hypertrophic Cardiomyopathy (HCM)
- Interventions
- Approved Hypertrophic Cardiomyopathy drug treatments, Mavacamten
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 331 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Healthy Participants
- Interventions
- Mavacamten Capsule 1, Mavacamten Capsule 2, Mavacamten Capsule 3
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 95 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 3
- States / cities
- Anaheim, California • Miami, Florida • Springfield, Missouri
- Conditions
- Breastfeeding, Hypertrophic Cardiomyopathy, Pregnancy Related
- Interventions
- Mavacamten
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 15 Years and older · Female only
- Enrollment
- 20 participants
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Wilmington, North Carolina
- Conditions
- Hypertrophic Cardiomyopathy
- Interventions
- MYK-461
- Drug
- Lead sponsor
- MyoKardia, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • Cypress, California • Stanford, California + 4 more
- Conditions
- Cardiomyopathy, Hypertrophic
- Interventions
- Mavacamten
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 7
- States / cities
- West Hollywood, California • Atlanta, Georgia • Boston, Massachusetts + 4 more
- Conditions
- Obstructive Hypertrophic Cardiomyopathy
- Interventions
- mavacamten
- Drug
- Lead sponsor
- Michael Ayers
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- mavacamten
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 16 more
- Conditions
- Obstructive Hypertrophic Cardiomyopathy
- Interventions
- Mavacamten, Non-mavacamten symptomatic oHCM therapy
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 60
- States / cities
- Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 48 more
- Conditions
- Obstructive Hypertrophic Cardiomyopathy
- Interventions
- mavacamten, Placebo
- Drug
- Lead sponsor
- MyoKardia, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 251 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 29
- States / cities
- Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 23 more
- Conditions
- Cardiomyopathy, Hypertrophic Obstructive, Left Ventricular Outflow Tract Obstruction
- Interventions
- MYK-461
- Drug
- Lead sponsor
- MyoKardia, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • New Haven, Connecticut • Boston, Massachusetts + 4 more
- Conditions
- Healthy Participants
- Interventions
- Mavacamten
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 158 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 4
- States / cities
- Miami, Florida • Springfield, Missouri • Austin, Texas
- Conditions
- HOCM, Hypertrophic Obstructive Cardiomyopathy
- Interventions
- Mavacamten, Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 21
- States / cities
- Los Angeles, California • Stanford, California • New Haven, Connecticut + 16 more
- Conditions
- Healthy Participants
- Interventions
- Mavacamten, Activated Charcoal with Sorbitol
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Cardiomyopathy, Hypertrophic
- Interventions
- Mavacamten, Placebo
- Drug · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 580 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 36 more
- Conditions
- Obstructive Hypertrophic Cardiomyopathy
- Interventions
- Mavacamten
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Healthy Participants
- Interventions
- Mavacamten
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 2
- States / cities
- Miami, Florida • Saint Paul, Minnesota
- Conditions
- Obstructive Hypertrophic Cardiomyopathy (oHCM)
- Interventions
- Mavacamten
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Hypertrophic Cardiomyopathy, Obstructive Hypertrophic Cardiomyopathy, Non-obstructive Hypertrophic Cardiomyopathy
- Interventions
- mavacamten
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 314 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 31
- States / cities
- Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 26 more
- Conditions
- Obstructive Hypertrophic Cardiomyopathy (oHCM)
- Interventions
- Mavacamten
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania